Compugen (CGEN) Corporate presentation summary

Vision and strategy

• Aims to transform patient lives by developing first-in-class therapeutics using an AI/ML-powered computational discovery platform, Unigen™.

• Focuses on novel immuno-oncology antibodies with a rich clinical pipeline and validating partnerships exceeding $1 billion in milestones plus royalties.

• Cash balance of $125.3M as of June 30, 2026, with expected runway into 2029.

Clinical pipeline and partnerships

• Fully-owned clinical assets include COM701 (anti-PVRIG) and COM902 (Fc-reduced anti-TIGIT).

• Rilvegostomig, a PD-1/TIGIT bispecific antibody (TIGIT from COM902), is in Phase 3 with AstraZeneca, targeting >$5B peak year revenue.

• GS-0321 (anti-IL-18BP) is licensed to Gilead, with Compugen responsible for preclinical and Phase 1 development.

• Early-stage pipeline includes multiple undisclosed assets.

Rilvegostomig and AstraZeneca collaboration

• Rilvegostomig is central to AstraZeneca’s IO backbone strategy, with 12 pivotal Phase 3 trials across NSCLC, GI, endometrial, and urothelial cancers.

• Compugen eligible for up to $195M in milestones and tiered royalties up to mid-single digit.

• AstraZeneca has rights to develop TIGIT bispecifics, while Compugen retains rights to PVRIG/TIGIT bispecifics.